SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : BCRX: Target practice for shorts
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (64)9/6/1999 5:55:00 PM
From: Wolff   of 96
 
Since the purpose of the NA inhibitors is to slow viral growth until the immune system kicks in in full force, you would not expect the drug to do much after about 2 days post infection in healthy patients. Realistically, the drug will probably not be administered in that time, so in most cases healthy patients with normal immune response probably won't derive much benefit from the drug.

Investors don't seem to realize that by the time a person has flu symptoms bad enough to seek treatment, recognizes that the "cold" is persisting and might be the flu, schedules a physician visit (add a couple of days for that), gets diagnosed with confirmed influenza, gets a prescription filled, and begins dosing, its already several days to a week post-infection and the immune system response is already kicking in.

Bottom line - the nature of influenza makes it quite unsuited for pharmacotherapy that targets viral replication - it won't provide much/any clinical benefit because it comes too late.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News